相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
免疫原详情见datasheet,该抗体亚型为:IgG1, kappa
- 保存条件:
-2°C-8°C
- 保质期:
1年
- 库存:
100
- 供应商:
艾美捷科技
- 宿主:
Human
- 应用范围:
ELISA,In vivo Neutralization,FCM
- 抗体英文名:
Human IL6, InVivo Block/Neutralizing Antibody
- 抗体名:
Human IL6, InVivo Block/Neutralizing Antibody
Human IL6, InVivo Block/Neutralizing Antibody,Human IL6, InVivo Block/Neutralizing Antibody,Human IL6, InVivo Block/Neutralizing Antibody,Human IL6, InVivo Block/Neutralizing Antibody
产品名称:Human IL6, InVivo Block/Neutralizing Antibody-Human IL6, InVivo Block/Neutralizing Antibody
产品货号:BGT-ANT-37375
产品规格:100ug#1mg

应用类型:ELISA,In vivo Neutralization,FCM

蛋白别名:Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor

Human IL6, InVivo Block/Neutralizing Antibody-Human IL6, InVivo Block/Neutralizing Antibody详情见产品datasheet
点击:Human IL6, InVivo Block/Neutralizing Antibody-Human IL6, InVivo Block/Neutralizing Antibody更多Biogradetech产品信息价格,货期,产品说明,百度搜“艾美捷科技”进入官网网站,查看具体产品且快速下单。

风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Human ELISPOT Protocol Human ELISPOT Protocol(TNFa,IL13, IL12,IL10, IL6,IL5,IL4,IL2,IL1b,IFNg ,FasL) the protocol is in the file below:
PPAR/ Agonist Increases the Expression of PGE2 Receptor Subtype EP4 in Human Lung Carcinoma Cells
an important role in the effort to help extend its dismal 5-year survival rate (2 (PGE2 ), and the prostag-landin E2 receptor subtype, EP4, promote the growth and progression of human nonsmall cell lung carcinoma (NSCLC), the most common lung carcinoma
Purification of Human Multiprotein Complexes using OneSTrEP Technology (PROT41)
complexes from human HeLa S3 cells in a scale and purity optimized for characterization by mass spectrometry. For this purpose, we use stably expressed One-STrEP -tag ® fusion proteins. This approach was successfully used in characterization of histone
技术资料暂无技术资料 索取技术资料







